Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Public ClinicalTrials.gov record NCT02499328. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Study identification
- NCT ID
- NCT02499328
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 340 participants
Conditions and interventions
Interventions
- AZD9150 Drug
- MEDI4736 Drug
- AZD5069 Drug
- tremelimumab (treme) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2015
- Primary completion
- Feb 27, 2020
- Completion
- Oct 7, 2025
- Last update posted
- Feb 10, 2026
2015 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Los Angeles | California | 90024 | — |
| Research Site | Los Angeles | California | 90089 | — |
| Research Site | Orange | California | 92868-3298 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Denver | Colorado | 80218 | — |
| Research Site | Plantation | Florida | 33324 | — |
| Research Site | Sarasota | Florida | 34232 | — |
| Research Site | Lafayette | Indiana | 47905 | — |
| Research Site | Boston | Massachusetts | 02111 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Billings | Montana | 59101 | — |
| Research Site | Morristown | New Jersey | 07960 | — |
| Research Site | Cincinnati | Ohio | 45267-2827 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
| Research Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02499328, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 10, 2026 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02499328 live on ClinicalTrials.gov.